Pub Date : 2023-07-14DOI: 10.37290/ctnr2641-452x.21:473-477
Qi Liao, Hui Pan, Zhiwu Zheng, Ying Yu
The effects of triple antibiotic therapy plus probiotics on Helicobacter pylori-induced peptic ulcers were assessed. To this end, patients diagnosed with Helicobacter pylori-induced peptic ulcers were divided into control and treatment groups. The control group received standardized triple antibiotic (rabeprazole sodium, amoxicillin, and clarithromycin) therapy, whereas the treatment group also received Compound Eosinophil-Lactobacillus tablets for 14 consecutive days. The treatment outcomes (Helicobacter pylori eradication rate, expression levels of serum procalcitonin, high-sensitivity C-reactive protein, and interleukin-8, and incidence of adverse events) were compared. The effective rate of peptic ulcer control and the eradication rate of Helicobacter pylori were significantly higher for the treatment group than those for the control group (P < 0.05). There was also a significant reduction in pro-inflammatory markers (procalcitonin, high-sensitivity C-reactive protein, and interleukin-8) in the treatment group compared to those in the control group (P < 0.05). Also, the incidence rate of adverse events in the treatment group was lower than that of the control group, but the difference was not statistically significant (P > 0.05). In conclusion, standardized triple antibiotic therapy plus probiotics can effectively improve treatment outcomes and the Helicobacter pylori eradication rate in patients with Helicobacter pylori-induced peptic ulcer.
本研究评估了三联抗生素疗法加益生菌对幽门螺旋杆菌诱发的消化性溃疡的影响。为此，将确诊为幽门螺旋杆菌诱发消化性溃疡的患者分为对照组和治疗组。对照组接受标准化的三联抗生素（雷贝拉唑钠、阿莫西林和克拉霉素）治疗，而治疗组还接受连续 14 天的复方嗜酸乳杆菌片治疗。比较了治疗效果（幽门螺杆菌根除率、血清降钙素原、高敏 C 反应蛋白和白细胞介素-8 的表达水平以及不良反应发生率）。治疗组的消化性溃疡有效控制率和幽门螺杆菌根除率明显高于对照组（P < 0.05）。治疗组的促炎指标（降钙素原、高敏 C 反应蛋白和白细胞介素-8）也明显低于对照组（P < 0.05）。此外，治疗组的不良反应发生率也低于对照组，但差异无统计学意义（P > 0.05）。总之，标准化三联抗生素疗法加益生菌能有效改善幽门螺旋杆菌引起的消化性溃疡患者的治疗效果和幽门螺旋杆菌根除率。
{"title":"Inclusion of Probiotics to Triple Antibiotic Therapy Improves the Outcome of Anti-Helicobacter pylori-Induced Peptic Ulcer","authors":"Qi Liao, Hui Pan, Zhiwu Zheng, Ying Yu","doi":"10.37290/ctnr2641-452x.21:473-477","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:473-477","url":null,"abstract":"The effects of triple antibiotic therapy plus probiotics on Helicobacter pylori-induced peptic ulcers were assessed. To this end, patients diagnosed with Helicobacter pylori-induced peptic ulcers were divided into control and treatment groups. The control group received standardized triple antibiotic (rabeprazole sodium, amoxicillin, and clarithromycin) therapy, whereas the treatment group also received Compound Eosinophil-Lactobacillus tablets for 14 consecutive days. The treatment outcomes (Helicobacter pylori eradication rate, expression levels of serum procalcitonin, high-sensitivity C-reactive protein, and interleukin-8, and incidence of adverse events) were compared. The effective rate of peptic ulcer control and the eradication rate of Helicobacter pylori were significantly higher for the treatment group than those for the control group (P < 0.05). There was also a significant reduction in pro-inflammatory markers (procalcitonin, high-sensitivity C-reactive protein, and interleukin-8) in the treatment group compared to those in the control group (P < 0.05). Also, the incidence rate of adverse events in the treatment group was lower than that of the control group, but the difference was not statistically significant (P > 0.05). In conclusion, standardized triple antibiotic therapy plus probiotics can effectively improve treatment outcomes and the Helicobacter pylori eradication rate in patients with Helicobacter pylori-induced peptic ulcer.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139359383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-13DOI: 10.37290/ctnr2641-452x.21:454-460
Jian Zeng, Zonghan Zhou
Cistanche is known to relieve cataracts; however, the active ingredients and mechanism of action of cistanche to relieve cataracts are unclear. At present, the active ingredients of cistanche were screened through the Traditional Chinese Medicine Systems Pharmacology website, and a total of six active ingredients were identified. Drug and disease targets were obtained through Swiss target prediction and the Genecard website, and a total of 172 common targets were identified. The biological functions and Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the targets were found to be concentrated in the phosphatidylinositol 3-kinase/protein kinase B, forkhead family of transcription factors, and mitogen-activated protein kinases pathways. The protein–protein interaction network was established, and phosphatidylinositol 3-kinase and protein kinase B-related genes were found to be the key genes. Molecular docking was carried out between the active ingredient and the key target, and it was found that the combination of the active ingredient and the key target was stable. In summary, cistanche can reduce cataracts by regulating the key targets of the active ingredients and thus alleviating cataracts.
{"title":"Network Pharmacology-Based Strategy to Reveal the Mechanism of Action of Cistanche Against Cataracts","authors":"Jian Zeng, Zonghan Zhou","doi":"10.37290/ctnr2641-452x.21:454-460","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:454-460","url":null,"abstract":"Cistanche is known to relieve cataracts; however, the active ingredients and mechanism of action of cistanche to relieve cataracts are unclear. At present, the active ingredients of cistanche were screened through the Traditional Chinese Medicine Systems Pharmacology website, and a total of six active ingredients were identified. Drug and disease targets were obtained through Swiss target prediction and the Genecard website, and a total of 172 common targets were identified. The biological functions and Kyoto Encyclopedia of Genes and Genomes pathway enrichment of the targets were found to be concentrated in the phosphatidylinositol 3-kinase/protein kinase B, forkhead family of transcription factors, and mitogen-activated protein kinases pathways. The protein–protein interaction network was established, and phosphatidylinositol 3-kinase and protein kinase B-related genes were found to be the key genes. Molecular docking was carried out between the active ingredient and the key target, and it was found that the combination of the active ingredient and the key target was stable. In summary, cistanche can reduce cataracts by regulating the key targets of the active ingredients and thus alleviating cataracts.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139359660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-13DOI: 10.37290/ctnr2641-452x.21:395-399
Weiwei Song, Dandan Zhu, Yinling Zhao
We have explored the efficacy of neoadjuvant chemotherapy in association with cytoreductive surgery and postoperative parenteral nutrition support in advanced ovarian cancer patients. The control group received cytoreductive surgery combined with postoperative conventional chemotherapy and fasted after surgery, whereas the treatment group received neoadjuvant chemotherapy combined with cytoreductive surgery and parenteral nutrition. In contrast to the control group, the operation time, hospital stay, amount of intraoperative blood loss, and abdominal fluid accumulation of the treatment group were diminished, the total effectiveness rate was elevated, serum levels of albumin, transferrin, and prealbumin were increased, levels of human epididymal protein 4, vascular endothelial growth factor, and carbohydrate antigen 125 were declined, and the Karnofky Performance Status score was higher. While there was no difference observed in the 1-year survival rate or total incidence of complications between the two groups, the quality of life of patients in the treatment group improved.
{"title":"Postoperative Parenteral Nutrition Support and Neoadjuvant Chemotherapy Combined with Cytoreductive Surgery Improve the Quality of Life, but Not the Survival Rate or Incidence of Complications","authors":"Weiwei Song, Dandan Zhu, Yinling Zhao","doi":"10.37290/ctnr2641-452x.21:395-399","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:395-399","url":null,"abstract":"We have explored the efficacy of neoadjuvant chemotherapy in association with cytoreductive surgery and postoperative parenteral nutrition support in advanced ovarian cancer patients. The control group received cytoreductive surgery combined with postoperative conventional chemotherapy and fasted after surgery, whereas the treatment group received neoadjuvant chemotherapy combined with cytoreductive surgery and parenteral nutrition. In contrast to the control group, the operation time, hospital stay, amount of intraoperative blood loss, and abdominal fluid accumulation of the treatment group were diminished, the total effectiveness rate was elevated, serum levels of albumin, transferrin, and prealbumin were increased, levels of human epididymal protein 4, vascular endothelial growth factor, and carbohydrate antigen 125 were declined, and the Karnofky Performance Status score was higher. While there was no difference observed in the 1-year survival rate or total incidence of complications between the two groups, the quality of life of patients in the treatment group improved.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139359917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-11DOI: 10.37290/ctnr2641-452x.21:411-416
Lei Hu, Chenhao Zhang, Hailin Dai, Chunliang Zhang, Yuejun Yang, Nan Wang, Fengli Zhao
Transdermal patches of rotigotine, a dopamine agonist of the non-ergoline class, are used to treat the signs and symptoms of Parkinson’s disease. In this study, we have probed the effect of ginseng oral liquid on the efficacy of the rotigotin patch plus amantadine in treating Parkinson’s disease. Measurements of mental behavior, daily activities, and motor function were used to calculate the total effective rate of the treatment that was elevated in the presence of ginseng oral liquid. While ginseng oral liquid lowered the Parkinson’s Disease Questionnaire scores and levels of serum amyloid A and interleukin-12, it augmented apolipoprotein A1. No difference was seen in the incidence of adverse events between the two groups. To sum up, rotigotin patches in association with amantadine and ginseng oral liquid are effective in treating Parkinson’s disease, which can effectively promote the quality of life of patients, decrease clinical symptoms, and reduce inflammatory reactions.
罗替戈汀是一种非麦角林类多巴胺激动剂，其透皮贴片可用于治疗帕金森病的症状和体征。在这项研究中，我们探讨了人参口服液对罗替戈汀贴剂加金刚烷胺治疗帕金森病疗效的影响。通过对精神行为、日常活动和运动功能的测量，我们计算出了在人参口服液存在的情况下治疗总有效率的升高。虽然人参口服液降低了帕金森病问卷的得分以及血清淀粉样蛋白 A 和白细胞介素-12 的水平，但却增加了载脂蛋白 A1。两组的不良反应发生率没有差异。综上所述，罗替戈汀贴剂联合金刚烷胺和人参口服液治疗帕金森病疗效显著，可有效提高患者的生活质量，减轻临床症状，减少炎症反应。
{"title":"Ginseng Oral Liquid Enhances Therapeutic Output of Rotigotin Patch Plus Amantadine in Parkinson’s Disease","authors":"Lei Hu, Chenhao Zhang, Hailin Dai, Chunliang Zhang, Yuejun Yang, Nan Wang, Fengli Zhao","doi":"10.37290/ctnr2641-452x.21:411-416","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:411-416","url":null,"abstract":"Transdermal patches of rotigotine, a dopamine agonist of the non-ergoline class, are used to treat the signs and symptoms of Parkinson’s disease. In this study, we have probed the effect of ginseng oral liquid on the efficacy of the rotigotin patch plus amantadine in treating Parkinson’s disease. Measurements of mental behavior, daily activities, and motor function were used to calculate the total effective rate of the treatment that was elevated in the presence of ginseng oral liquid. While ginseng oral liquid lowered the Parkinson’s Disease Questionnaire scores and levels of serum amyloid A and interleukin-12, it augmented apolipoprotein A1. No difference was seen in the incidence of adverse events between the two groups. To sum up, rotigotin patches in association with amantadine and ginseng oral liquid are effective in treating Parkinson’s disease, which can effectively promote the quality of life of patients, decrease clinical symptoms, and reduce inflammatory reactions.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139360377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-10DOI: 10.37290/ctnr2641-452x.21:490-494
Hui Shi, Shanshan Li
We have examined the influence of early postoperative nutritional nursing on the prognosis of patients undergoing gastrointestinal surgery. A total of 82 patients with gastrointestinal surgery were recruited from the First Affiliated Hospital of Soochow University between January 2020 and December 2022 for this study. The patients were divided into two equalsized control and treatment groups. The control group received routine care, whereas the treatment group received added nutritional care. Compared to the control group, the first exhaust time, first defecation time, and hospitalization time in the treatment group were shorter (P < 0.01). On the 7th day after surgery, no difference was found in the levels of albumin and total protein between the two groups (P > 0.05). However, on the 4th and 7th days after surgery, the diamine oxidase and malondialdehyde values in the treatment group were lower relative to the control group. Body weight in the treatment group was higher, the incidence of complications was lower, and the quality-of-life score and immune function were better compared to the control group (P < 0.05). To sum up, early nutritional care is beneficial to improving the immune function indexes, nutritional indexes, and quality of life of patients after gastrointestinal surgery, as well as reducing the occurrence of postoperative adverse reactions.
{"title":"Effect of Early Postoperative Nutritional Nursing on the Prognosis of Patients Undergoing Gastrointestinal Surgery","authors":"Hui Shi, Shanshan Li","doi":"10.37290/ctnr2641-452x.21:490-494","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:490-494","url":null,"abstract":"We have examined the influence of early postoperative nutritional nursing on the prognosis of patients undergoing gastrointestinal surgery. A total of 82 patients with gastrointestinal surgery were recruited from the First Affiliated Hospital of Soochow University between January 2020 and December 2022 for this study. The patients were divided into two equalsized control and treatment groups. The control group received routine care, whereas the treatment group received added nutritional care. Compared to the control group, the first exhaust time, first defecation time, and hospitalization time in the treatment group were shorter (P < 0.01). On the 7th day after surgery, no difference was found in the levels of albumin and total protein between the two groups (P > 0.05). However, on the 4th and 7th days after surgery, the diamine oxidase and malondialdehyde values in the treatment group were lower relative to the control group. Body weight in the treatment group was higher, the incidence of complications was lower, and the quality-of-life score and immune function were better compared to the control group (P < 0.05). To sum up, early nutritional care is beneficial to improving the immune function indexes, nutritional indexes, and quality of life of patients after gastrointestinal surgery, as well as reducing the occurrence of postoperative adverse reactions.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139360675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:222-227
Yan Sun, Yuxia Zhao, Yulong Liu, Zilang Yu, Fanrong Wu
Patients with coronary heart disease and angina pectoris were divided into two groups (control and treatment) of 54 patients per group. The control group received puerarin, whereas the treatment group received puerarin plus nicorandil. Therapeutic outcomes of two treatments were compared by assessing lower left ventricular end systolic diameter, lower left ventricular end diastolic diameter, higher left ventricular ejection fraction, duration of angina pectoris, number of angina attacks, dosage of nitroglycerin needed, plasma viscosity, whole blood viscosity, fibrinogen level, pro-inflammatory markers, as well as 36-item Short Form Survey scores. The total therapeutic rate was better in the group receiving both puerarin and nicorandil than puerarin alone. No difference was discovered in the incidence of adverse reactions between the two groups. This led us to conclude that puerarin combined with nicorandil is more effective in treating coronary heart disease and angina pectoris and can improve cardiac functions, lessen chemodynamic indexes and inflammatory reactions of angina pectoris, and promote the quality of life of patients.
{"title":"Puerarin Combined with Nicorandil is More Effective in Treating Coronary Heart Disease and Angina Pectoris","authors":"Yan Sun, Yuxia Zhao, Yulong Liu, Zilang Yu, Fanrong Wu","doi":"10.37290/ctnr2641-452x.21:222-227","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:222-227","url":null,"abstract":"Patients with coronary heart disease and angina pectoris were divided into two groups (control and treatment) of 54 patients per group. The control group received puerarin, whereas the treatment group received puerarin plus nicorandil. Therapeutic outcomes of two treatments were compared by assessing lower left ventricular end systolic diameter, lower left ventricular end diastolic diameter, higher left ventricular ejection fraction, duration of angina pectoris, number of angina attacks, dosage of nitroglycerin needed, plasma viscosity, whole blood viscosity, fibrinogen level, pro-inflammatory markers, as well as 36-item Short Form Survey scores. The total therapeutic rate was better in the group receiving both puerarin and nicorandil than puerarin alone. No difference was discovered in the incidence of adverse reactions between the two groups. This led us to conclude that puerarin combined with nicorandil is more effective in treating coronary heart disease and angina pectoris and can improve cardiac functions, lessen chemodynamic indexes and inflammatory reactions of angina pectoris, and promote the quality of life of patients.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69758093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:242-247
T. Matsuo, C. Yokoyama, Takako Yamada, T. Iida, S. Mochizuki, A. Yoshihara, K. Akimitsu
Medium-chain triglycerides, lipids containing three 6−12 carbon medium-chain fatty acids, have antiobesity effects because they do not promote lipogenesis. d-Allulose, a low-calorie epimer of fructose commercially used as a low-calorie sweetener, suppresses hepatic lipogenesis and enhances postprandial fat oxidation. Therefore, we have explored whether a simultaneous intake of medium-chain fatty acids and d-allulose may exhibit a greater reduction in de novo lipogenesis and increase their antiobesity effects. To this end, 32 male Wistar rats were divided into four treatment groups of equal sizes: control, 3% d-allulose-treated, 5% medium-chain triglycerides-treated, and 3% d-allulose + 5% medium-chain triglycerides-treated. After 8 weeks of ad libitum exposure to these diets, d-allulose significantly decreased intra-abdominal adipose tissue and total body fat weight, with or without medium-chain triglyceride supplementation. The antiobesity effect of d-allulose was observed with or without dietary medium-chain triglyceride supplementation in high-fat diet-induced obese rats, but no synergistic effect was detected between d-allulose and medium-chain triglycerides.
{"title":"Effect of Simultaneous Intake of Medium-Chain Triglyceride and d-Allulose on Body Fat Accumulation in Rats Fed a High-Fat Diet","authors":"T. Matsuo, C. Yokoyama, Takako Yamada, T. Iida, S. Mochizuki, A. Yoshihara, K. Akimitsu","doi":"10.37290/ctnr2641-452x.21:242-247","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:242-247","url":null,"abstract":"Medium-chain triglycerides, lipids containing three 6−12 carbon medium-chain fatty acids, have antiobesity effects because they do not promote lipogenesis. d-Allulose, a low-calorie epimer of fructose commercially used as a low-calorie sweetener, suppresses hepatic lipogenesis and enhances postprandial fat oxidation. Therefore, we have explored whether a simultaneous intake of medium-chain fatty acids and d-allulose may exhibit a greater reduction in de novo lipogenesis and increase their antiobesity effects. To this end, 32 male Wistar rats were divided into four treatment groups of equal sizes: control, 3% d-allulose-treated, 5% medium-chain triglycerides-treated, and 3% d-allulose + 5% medium-chain triglycerides-treated. After 8 weeks of ad libitum exposure to these diets, d-allulose significantly decreased intra-abdominal adipose tissue and total body fat weight, with or without medium-chain triglyceride supplementation. The antiobesity effect of d-allulose was observed with or without dietary medium-chain triglyceride supplementation in high-fat diet-induced obese rats, but no synergistic effect was detected between d-allulose and medium-chain triglycerides.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69758107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:215-221
Xiang-qin Wen, Xiaojin Yang
Amarogentin, a secoiridoid glycoside isolated from the Indian medicinal plant Swertia chirata, is widely known for its antileishmanial, antioxidative, hypoglycemic, antihepatotoxic, antimalarial, anti-inflammatory, and antimicrobial activities. It has been evaluated for its possible anticancerous role in lung cancer using A549 and H1299 cells as models. The results of these studies show a dose-dependent decrease in cell proliferation, cell migration, and invasion by amarogentin. Furthermore, amarogentin repressed stemness in lung cancer, as shown by a diminution in the expression of DLL4, NICD, and Hes1 proteins. In conclusion, we report for the first time the potential regulatory impact of amarogentin on lung cancer. These findings reveal that amarogentin treatment inhibits tumor stem cell-like features in lung cancer by regulating Notch signaling. Therefore, amarogentin may be deemed as a useful therapeutic drug for lung cancer.
{"title":"Amarogentin Inhibits Tumor Stem Cell-Like Features of Lung Cancer by Regulating Notch Signaling","authors":"Xiang-qin Wen, Xiaojin Yang","doi":"10.37290/ctnr2641-452x.21:215-221","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:215-221","url":null,"abstract":"Amarogentin, a secoiridoid glycoside isolated from the Indian medicinal plant Swertia chirata, is widely known for its antileishmanial, antioxidative, hypoglycemic, antihepatotoxic, antimalarial, anti-inflammatory, and antimicrobial activities. It has been evaluated for its possible anticancerous role in lung cancer using A549 and H1299 cells as models. The results of these studies show a dose-dependent decrease in cell proliferation, cell migration, and invasion by amarogentin. Furthermore, amarogentin repressed stemness in lung cancer, as shown by a diminution in the expression of DLL4, NICD, and Hes1 proteins. In conclusion, we report for the first time the potential regulatory impact of amarogentin on lung cancer. These findings reveal that amarogentin treatment inhibits tumor stem cell-like features in lung cancer by regulating Notch signaling. Therefore, amarogentin may be deemed as a useful therapeutic drug for lung cancer.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47964933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-07DOI: 10.37290/ctnr2641-452x.21:235-241
D. Korovljev, Dejan Javorac, N. Todorovic, Marijana Ranisavljev, D. Engeset, Tonje Holte Stea, J. Ostojić, Katarina Bijelić, Branislava Srdjenović Čonić, N. Kladar, L. Rátgéber, Nenad Trunić, Sava Rajkovic, V. Štajer, S. Ostojić
The aim of this randomized controlled trial was to analyze the effects of medium-term supplementation with hydrogen-rich water on brain metabolism, appetite-regulating hormones, body composition, and safety biomarkers in overweight adults. Twenty (n = 20, 10 females) apparently healthy adults with a body mass index >24.9 kg/m2 were assigned to receive 0.5 L per day of hydrogen-rich water (7.5 mg of hydrogen) or hydrogen-free water (tap water) for 12 weeks. Two-way analysis of variance with repeated measures revealed a significant difference between the two interventions in several body composition indices (P ≤ 0.05), with hydrogen-rich water superior to placebo to reduce waist circumference and mid-upper arm circumference by 1.31 cm (95% confidence interval, from –0.23 to 2.85) and 0.65 cm (95% confidence interval, from –0.10 to 1.40), respectively. Hydrogen-rich water outcompeted placebo to raise serum ghrelin levels, as the mean difference from the placebo group was 17.28 pmol/L (95% confidence interval, from 1.81 to 32.75) (P = 0.02). A non-significant strong positive trend (P = 0.10) was reported toward hydrogen-rich water being superior to placebo in augmenting total serum short-chain fatty acid levels, with a mean difference from the control group of 195.6 μmol/L (95% confidence interval, from –64.55 to 275.85). The mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03). Our findings advance hydrogen-rich water as a promising metabolic intervention in overweight adults, but further validation via multicentric longitudinal randomized controlled trials in metabolic and nutritional disorders is required.
{"title":"The Effects of 12-Week Hydrogen-Rich Water Intake on Body Composition, Short-Chain Fatty Acids Turnover, and Brain Metabolism in Overweight Adults: A Randomized Controlled Trial","authors":"D. Korovljev, Dejan Javorac, N. Todorovic, Marijana Ranisavljev, D. Engeset, Tonje Holte Stea, J. Ostojić, Katarina Bijelić, Branislava Srdjenović Čonić, N. Kladar, L. Rátgéber, Nenad Trunić, Sava Rajkovic, V. Štajer, S. Ostojić","doi":"10.37290/ctnr2641-452x.21:235-241","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:235-241","url":null,"abstract":"The aim of this randomized controlled trial was to analyze the effects of medium-term supplementation with hydrogen-rich water on brain metabolism, appetite-regulating hormones, body composition, and safety biomarkers in overweight adults. Twenty (n = 20, 10 females) apparently healthy adults with a body mass index >24.9 kg/m2 were assigned to receive 0.5 L per day of hydrogen-rich water (7.5 mg of hydrogen) or hydrogen-free water (tap water) for 12 weeks. Two-way analysis of variance with repeated measures revealed a significant difference between the two interventions in several body composition indices (P ≤ 0.05), with hydrogen-rich water superior to placebo to reduce waist circumference and mid-upper arm circumference by 1.31 cm (95% confidence interval, from –0.23 to 2.85) and 0.65 cm (95% confidence interval, from –0.10 to 1.40), respectively. Hydrogen-rich water outcompeted placebo to raise serum ghrelin levels, as the mean difference from the placebo group was 17.28 pmol/L (95% confidence interval, from 1.81 to 32.75) (P = 0.02). A non-significant strong positive trend (P = 0.10) was reported toward hydrogen-rich water being superior to placebo in augmenting total serum short-chain fatty acid levels, with a mean difference from the control group of 195.6 μmol/L (95% confidence interval, from –64.55 to 275.85). The mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03). Our findings advance hydrogen-rich water as a promising metabolic intervention in overweight adults, but further validation via multicentric longitudinal randomized controlled trials in metabolic and nutritional disorders is required.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48793610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study was designed to evaluate the effect of Bifidobacterium triple viable granules combined with montmorillonite powder in children with diarrhea. To this end, 60 children with diarrhea were divided into two groups of equal size, with one receiving montmorillonite powder alone (control) and the other receiving montmorillonite powder plus Bifidobacterium triple viable granules (treatment). The children in the treatment group experienced significantly higher overall relief from diarrhea that was associated with shorter durations of fever, diarrhea, abdominal pain, and vomiting, as well as shorter recovery times for stool characters and stool frequency. Also, the serum levels of C-reactive protein, Interleukin-4, and Interleukin-6 were lower, while Immunoglobulin A, Immunoglobulin G, and Immunoglobulin M levels were higher in the treatment group than the control group (P < 0.05). There were far fewer adverse reactions in the treatment group than in the control group. In summary, Bifidobacterium triple viable granules combined with montmorillonite powder are clinically superior in treating children with diarrhea.
{"title":"Bifidobacterium Triple Viable Granules Combined with Montmorillonite Powder in the Therapy of Children with Diarrhea","authors":"Wendi Jin, Er-te Yu, Yunbing Lu, Zhaolin Wang, Li Huang, X. Qiao","doi":"10.37290/ctnr2641-452x.21:272-276","DOIUrl":"https://doi.org/10.37290/ctnr2641-452x.21:272-276","url":null,"abstract":"This study was designed to evaluate the effect of Bifidobacterium triple viable granules combined with montmorillonite powder in children with diarrhea. To this end, 60 children with diarrhea were divided into two groups of equal size, with one receiving montmorillonite powder alone (control) and the other receiving montmorillonite powder plus Bifidobacterium triple viable granules (treatment). The children in the treatment group experienced significantly higher overall relief from diarrhea that was associated with shorter durations of fever, diarrhea, abdominal pain, and vomiting, as well as shorter recovery times for stool characters and stool frequency. Also, the serum levels of C-reactive protein, Interleukin-4, and Interleukin-6 were lower, while Immunoglobulin A, Immunoglobulin G, and Immunoglobulin M levels were higher in the treatment group than the control group (P < 0.05). There were far fewer adverse reactions in the treatment group than in the control group. In summary, Bifidobacterium triple viable granules combined with montmorillonite powder are clinically superior in treating children with diarrhea.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42403007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：